Hot Products

Brevifolincarboxylic acid
Catalog No: CFN93653

Brevifolincarboxylic acid shows moderate antibacterial activity against Salmonella enteritidis , Salmonella typhimurium , and Salmonella abony, it (IC50 = 18.0 uM) also shows good antioxidant activity. Brevifolincarboxylic acid shows marked inhibitory effects on aryl hydrocarbon receptor -based bioassay activation by TCDD, and its effect is dose dependent.

Brevilin A
Catalog No: CFN99694

Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs. Brevilin A shows antigiardial activity (IC50 = 16.1 μM) and is similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM).

Breviscapine
Catalog No: CFN90315

Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway .

Britannilactone
Catalog No: CFN92601

Britannilactone significantly reduces melanin production in a dose-dependent manner with the IC50 value of 15.5 uM.

Britannin
Catalog No: CFN90220

Britannin has strong cytotoxicity to HepG-2, MCF-7, MDBK and A-549 cells (IC50: 2.2, 5.9, 5.4, and 3.5 microg/mL, respectively). Britannin inhibits growth of MCF-7 and MDA-MB-468 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may potentially serve as an agent for breast cancer therapy.

Broussoflavonol B
Catalog No: CFN92774

Broussoflavonol B is a potent growth inhibitor of ER-negative breast cancer stem-like cells, may be used to treat breast cancer. Broussoflavonol B increases the growth inhibitory activity of tamoxifen in tumorsphere cells derived from MCF7/TAM cells.

Broussonin A
Catalog No: CFN97694

Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin A shows estrogenic activity with ligand-binding activity of estrogen receptor, transcriptional activity of estrogen-responsive element-luciferase reporter genes. Broussonin A can significantly inhibit adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay; it suppresses lipopolysaccharide (LPS)-stimulated inducible nitric oxide synthase (iNOS) expression at the transcriptional level through modulating NF-κB and down-regulation of the Akt and ERK signaling pathways.

Broussonin B
Catalog No: CFN97695

Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin B can induce neurite outgrowth in PC-12 cells at concentration of 50 microg/ml, and show moderate inhibitory activities against a chymotrypsin-like activity of the proteasome.Broussonin B also can significantly inhibit adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay.

Broussonin E
Catalog No: CFN97474

Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway, and can be further developed as a promising drug for the treatment of inflammation-related diseases such as atherosclerosis.

Bruceantin
Catalog No: CFN89339

Bruceantin has antiviral activity, it can inhibit pepper mottle virus in pepper; it also shows high antimalarial activity. Bruceantin is an effective agent in controlling the proliferation, viability and migration of multiple myeloma cancer stem cells (CSCs) as well as angiogenesis in vitro. Bruceantin exhibits NF-κB p65 inhibition, and cytotoxic potential against HT-29, HeLa, and HL-60 cells .